DNTH Stock Price | Dianthus Therapeutics Inc. P/E, Revenue, EPS, & Forecasts

Dianthus Therapeutics Inc. • DNTH

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Dianthus Therapeutics Inc.

Ticker

DNTH

Trading on

NASDAQ

ISIN

US2528281080

Industry

Biotechnology

Sector

Healthcare

CEO

Marino Garcia M.B.A.

Headquarters

7 Times Square, New York, NY, United States, 10036

Employees

Website

https://dianthustx.com

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Metrics

BasicAdvanced

Market cap

$553M

P/E ratio

EPS

-$2.83

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-117M

Ex dividend date

Price & volume

Market cap

$553M

Average daily volume

0.3M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

84.79

Price to book

1.68

Earnings

EPS

-$2.83

EPS estimate (current quarter)

-$0.71

EPS estimate (next quarter)

-$0.80

EBITDA

$-117M

Revenues (TTM)

$6.5M

Revenues per share (TTM)

$0.18

Technicals

Beta

52-week High

$32.27

52-week Low

$13.37

50-day moving average

$19.15

200-day moving average

$22.80

Short ratio

24.94

Short %

24.39%

Management effectiveness

ROE (TTM)

-28.73%

ROA (TTM)

-20.04%

Profit margin

0.00%

Gross profit margin

$6.5M

Operating margin

-2,852.71%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

33.10%

Share stats

Outstanding Shares

32.2M

Float

11M

Insiders %

7.87%

Institutions %

119.90%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 12 analysts.

Average price target

$51.40

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.51

-$0.55

7.27%

Q2 • 24Beat

-$0.72

-$0.59

-22.03%

Q3 • 24Missed

-$0.81

-$0.76

-6.58%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$1.3M

$-28.4M

-2,144.80%

Q4 • 24

$1.2M

$-29.5M

-2,537.49%

Q1 • 25

-12.29%

3.77%

18.31%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$374M

$21.5M

5.76%

Q4 • 24

$349M

$20M

5.73%

Q1 • 25

-6.80%

-7.23%

-0.46%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-27.4M

$-23.1M

$39.7M

$-27.5M

Q4 • 24

$-27.6M

$14.8M

$0.2M

$-27.7M

Q1 • 25

0.68%

-164.02%

-99.59%

0.65%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Dianthus Therapeutics Inc. share?

Dianthus Therapeutics Inc. shares are currently traded for undefined per share.

How many shares does Dianthus Therapeutics Inc. have?

Dianthus Therapeutics Inc. currently has 32.2M shares.

Does Dianthus Therapeutics Inc. pay dividends?

No, Dianthus Therapeutics Inc. doesn't pay dividends.

What is Dianthus Therapeutics Inc. 52 week high?

Dianthus Therapeutics Inc. 52 week high is $32.27.

What is Dianthus Therapeutics Inc. 52 week low?

Dianthus Therapeutics Inc. 52 week low is $13.37.

What is the 200-day moving average of Dianthus Therapeutics Inc.?

Dianthus Therapeutics Inc. 200-day moving average is $22.80.

Who is Dianthus Therapeutics Inc. CEO?

The CEO of Dianthus Therapeutics Inc. is Marino Garcia M.B.A..

How many employees Dianthus Therapeutics Inc. has?

Dianthus Therapeutics Inc. has 78 employees.

What is the market cap of Dianthus Therapeutics Inc.?

The market cap of Dianthus Therapeutics Inc. is $553M.

What is the P/E of Dianthus Therapeutics Inc.?

The current P/E of Dianthus Therapeutics Inc. is null.

What is the EPS of Dianthus Therapeutics Inc.?

The EPS of Dianthus Therapeutics Inc. is -$2.83.

What is the PEG Ratio of Dianthus Therapeutics Inc.?

The PEG Ratio of Dianthus Therapeutics Inc. is null.

What do analysts say about Dianthus Therapeutics Inc.?

According to the analysts Dianthus Therapeutics Inc. is considered a buy.